Long-term Risankizumab Treatment Outperforms Placebo in PsA

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

Related Keywords

Joseph Merola ,Harvard Medical School ,Lupus Foundation Joseph Merola ,Department Of Dermatology At Brigham ,Peuropean League Against Rheumatism ,American College Of Rheumatology ,Group For Research ,American College Of Rheumatology National Psoriasis Foundation ,Lupus Foundation ,Psoriatic Arthritis ,American College ,National Psoriasis Foundation ,Harvard Medical ,Psoriasis Area ,Severity Index ,